摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[4-(2-chloropyrimidin-4-yl)phenyl]methanol | 281232-97-1

中文名称
——
中文别名
——
英文名称
[4-(2-chloropyrimidin-4-yl)phenyl]methanol
英文别名
——
[4-(2-chloropyrimidin-4-yl)phenyl]methanol化学式
CAS
281232-97-1
化学式
C11H9ClN2O
mdl
——
分子量
220.658
InChiKey
HXIRTIFQNCLFEL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.09
  • 拓扑面积:
    46
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds
    申请人:Aventis Pharmaceuticals Inc.
    公开号:US20030153604A1
    公开(公告)日:2003-08-14
    This invention is directed to an (aminoiminomethyl or aminomethyl)benzoheteroaryl compound of formula I which is useful for inhibiting the activity of Factor Xa by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.
    本发明涉及一种公式I的(氨基亚甲基或氨基甲基)苯并杂环化合物,该化合物通过与含有Xa因子的组合物结合来抑制Xa因子的活性。本发明还涉及含有公式I化合物的组合物、它们的制备方法以及它们的用途,例如抑制凝血酶的形成或治疗患有或受到与生理上有害的过量凝血酶相关的疾病状态的患者。
  • SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS
    申请人:Aventis Pharmaceuticals Products Inc.
    公开号:EP1140901A2
    公开(公告)日:2001-10-10
  • 4-ARYL-2-ANILINO-PYRIMIDINES AS PLK KINASE INHIBITORS
    申请人:Janssen Pharmaceutica, N.V.
    公开号:EP2283024B1
    公开(公告)日:2013-05-15
  • 4-ARYL-2-ANILINO-PYRIMIDINES
    申请人:Buijnsters Peter Jacobus Johannes
    公开号:US20110009404A1
    公开(公告)日:2011-01-13
    The present invention relates to compounds of Formula (Ia) or (Ib), the N-oxide forms, pharmaceutically acceptable addition salts, quaternary amines, stereoisomers, tautomers, racemics, metabolites, prodrugs, hydrates, or solvates thereof, wherein Y 1 , m, n, R 1 ; X 1 ; X 2 ; R 2 ; X 3 ; X 4 ; R 3 ; and R 4 have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to compounds that are kinase inhibitors useful for the treatment of disease states mediated by kinase, especially PLK4, in particular such compounds that are useful in the treatment of pathological processes which involve an aberrant cellular proliferation, such as tumor growth, rheumatoid arthritis, restenosis and atherosclerosis.
  • US6541505B1
    申请人:——
    公开号:US6541505B1
    公开(公告)日:2003-04-01
查看更多